Managing Trace Elements in Parenteral Nutrition
A new website providing educational content and treatment guidelines
Dedicated to Alleviating Drug Shortages
We are committed to collaborating with the FDA to prevent or mitigate drug shortages that impact the health of patients.
Check Product Availability
Updated September 23, 2023
HydrALAZINE Hydrochloride
- 20 mg/mL | 1 mL Single Dose Vial
- Shelf Pack — 25
Papaverine HCL
- 30 mg/mL | 2 mL Single Dose Vial
- Shelf Pack — 25
Zinc Sulfate
- 5 mg/mL | 5 mL Pharmacy Bulk Package Vial
- Shelf Pack — 25
News Center
American Regent Announces Results from Phase 3 HEART-FID Trial with INJECTAFER®
Shirley, NY–August 26, 2023: American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF).
INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
Basking Ridge, NJ and Shirley, NY – June 5, 2023: Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity.
St. John’s University and American Regent Post-Doctoral Pharmaceutical Industry Fellowship Now Recruiting
Melville, NY – September 14, 2023:
Learn more about the St. John’s University and American Regent Post-Doctoral Pharmaceutical Industry Fellowship by downloading our brochure. Information on how to apply to our program as well as key deadlines are included.